Inflammatory Bowel Disease Risk Variants Are Associated with an Increased Risk of Skin Cancer
Authors:
- 8 January 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Inflammatory Bowel Diseases
- Vol. 28 (11) , 1667-1676
Abstract
Inflammatory bowel disease is associated with an increased risk of skin cancer. The aims of this study were to determine whether IBD susceptibility variants are also associated with skin cancer susceptibility and if such risk is augmented by use of immune-suppressive therapy. The discovery cohort included participants in the UK Biobank. The validation cohort included participants in the Michigan Genomics Initiative. The primary outcome of interest was skin cancer, subgrouped into nonmelanoma skin cancers (NMSC) and melanoma skin cancers (MSC). Multivariable logistic regression with matched controls (3 controls:1 case) was performed to identify genomic predictors of skin malignancy in the discovery cohort. Variants with P < .05 were tested for replication in the validation cohort. Validated Single nucleotide polymorphisms were then evaluated for effect modification by immune-suppressive medications. The discovery cohort included 10,247 cases of NMSC and 1883 cases of MSC. The validation cohort included 7334 cases of NMSC and 3304 cases of MSC. Twenty-nine variants were associated with risk of NMSC in the discovery cohort, of which 5 replicated in the validation cohort (increased risk, rs7773324-A [DUSP22; IRF4], rs2476601-G [PTPN22], rs1847472-C [BACH2], rs72810983-A [CPEB4]; decreased risk, rs6088765-G [PROCR; MMP24]). Twelve variants were associated with risk of MSC in the discovery cohort, of which 4 were replicated in the validation cohort (increased risk, rs61839660-T [IL2RA]; decreased risk, rs17391694-C [GIPC2; MGC27382], rs6088765-G [PROCR; MMP24], and rs1728785-C [ZFP90]). No effect modification was observed. The results of this study highlight shared genetic susceptibility across IBD and skin cancer, with increased risk of NMSC in those who carry risk variants in IRF4, PTPN22, CPEB4, and BACH2 and increased risk of MSC in those who carry a risk variant in IL2RA.Keywords
All Related Versions
Funding Information
- K.C.C. (K24-AR076975)
- J.M.K.
This publication has 44 references indexed in Scilit:
- Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's diseaseAnnals of the Rheumatic Diseases, 2013
- Risk of Melanoma and Nonmelanoma Skin Cancer Among Patients With Inflammatory Bowel DiseaseGastroenterology, 2012
- Unexpected role of anticoagulant protein C in controlling epithelial barrier integrity and intestinal inflammationProceedings of the National Academy of Sciences, 2011
- Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel DiseaseGastroenterology, 2011
- Differential association of two PTPN22 coding variants with Crohnʼs disease and ulcerative colitisInflammatory Bowel Diseases, 2011
- IRF4 regulates IL-17A promoter activity and controls RORγt-dependent Th17 colitis in vivoInflammatory Bowel Diseases, 2011
- Interleukin-2 Receptor Signaling: At the Interface between Tolerance and ImmunityImmunity, 2010
- METAL: fast and efficient meta-analysis of genomewide association scansBioinformatics, 2010
- Increased Risk for Non-Melanoma Skin Cancer in Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2010
- Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.Journal of Experimental Medicine, 1985